Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Daito Pharmaceutical Co., Ltd. Buys Back 225,600 Shares for ¥303 million
Source disclosure: February 02, 2026
Daito Pharmaceutical Co., Ltd. [4577.T]
TOKYO, Feb 02 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) announced progress on its share repurchase program.
The company acquired 225,600 shares for a total of ¥303 million through open market purchases. The board authorized the repurchase of up to 1.00 million shares with a maximum expenditure of ¥1.5 billion.
The program is 59.7% complete with 597,200 shares acquired to date.
AI-tra
TOKYO, Feb 02 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) announced progress on its share repurchase program.
The company acquired 225,600 shares for a total of ¥303 million through open market purchases. The board authorized the repurchase of up to 1.00 million shares with a maximum expenditure of ¥1.5 billion.
The program is 59.7% complete with 597,200 shares acquired to date.